Hellmann MD, Paz-Ares L, Caro RB, et al. - In this open-label, phase 3 trial, experts randomized individuals with stage IV or recurrent non–small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy to evaluate the long-term advantage of nivolumab plus ipilimumab in patients with NSCLC. In comparison with chemotherapy, first-line treatment with nivolumab plus ipilimumab led to a longer duration of overall survival in patients with NSCLC, irrespective of the PD-L1 expression level. Moreover, no new safety issues emanated with longer follow-up.